Antihypertensive Drugs and COVID-19 Risk: A Cohort Study of 2 Million Hypertensive Patients.

To our knowledge, apart from one study which reported a positive association, 24 most studies, including several meta-analyses, concluded on either no association or a negative trend with COVID-19 risk or severity. 6 – 13 , 25 – 29 These studies can have a risk of confounding bias or collider bias. 30 , 31 To limit confounding, we restricted the study population to a more homogeneous population of treated hypertensive patients with no known cardiovascular comorbidity and no major comorbidity suspected to increase the risk of COVID-19. 32 We selected patients younger than 80 years treated over a long period of time with drugs with similar indications in 3 mutually exclusive classes of antihypertensive drugs to limit indication bias and confounding.

also in 4,201 other papers